Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:5520
Name head and neck squamous cell carcinoma
Definition A head and neck carcinoma that has_material_basis_in squamous cells that line the moist, mucosal surfaces inside the head and neck.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer head and neck cancer head and neck carcinoma head and neck squamous cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Buparlisib head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Adavosertib head and neck squamous cell carcinoma not applicable detail...
PIK3CA act mut Gedatolisib head and neck squamous cell carcinoma sensitive detail...
PIK3CA E545K Rigosertib Sodium head and neck squamous cell carcinoma sensitive detail...
Unknown unknown Metformin head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Sirolimus head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Temsirolimus head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Gedatolisib head and neck squamous cell carcinoma not applicable detail...
NOTCH1 C478F LGK974 head and neck squamous cell carcinoma sensitive detail...
FGFR1 over exp Infigratinib head and neck squamous cell carcinoma sensitive detail...
FBXW7 R505C Vorinostat head and neck squamous cell carcinoma sensitive detail...
PIK3CA mutant Radiotherapy + Taselisib head and neck squamous cell carcinoma sensitive detail...
PIK3CA amp Radiotherapy + Taselisib head and neck squamous cell carcinoma sensitive detail...
FGFR3 over exp Rogaratinib head and neck squamous cell carcinoma sensitive detail...
Unknown unknown Combretastatin A1 Diphosphate head and neck squamous cell carcinoma not applicable detail...
HRAS Q61L Sirolimus + Trametinib head and neck squamous cell carcinoma sensitive detail...
PIK3CA H1047R Sirolimus + Trametinib head and neck squamous cell carcinoma sensitive detail...
PIK3CA H1047R Radiotherapy + Taselisib head and neck squamous cell carcinoma sensitive detail...
Unknown unknown Cetuximab head and neck squamous cell carcinoma not applicable detail...
PIK3CA E542K GDC-0980 head and neck squamous cell carcinoma sensitive detail...
Unknown unknown Abemaciclib head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Abemaciclib + Everolimus head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Abemaciclib + Torin 2 head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Cetuximab + Fluorouracil head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Pembrolizumab head and neck squamous cell carcinoma not applicable detail...
ERBB4 G1109C Erlotinib head and neck squamous cell carcinoma no benefit detail...
ERBB4 G1109C Cetuximab head and neck squamous cell carcinoma no benefit detail...
ERBB4 G1109C Afatinib head and neck squamous cell carcinoma sensitive detail...
PIK3CA over exp Gedatolisib head and neck squamous cell carcinoma sensitive detail...
PIK3CA H1047R Gedatolisib head and neck squamous cell carcinoma sensitive detail...
FGFR3 D788N Infigratinib head and neck squamous cell carcinoma no benefit detail...
FGFR3 S131L Infigratinib head and neck squamous cell carcinoma decreased response detail...
Unknown unknown Nivolumab head and neck squamous cell carcinoma not applicable detail...
FGFR1 positive AZD4547 + Vistusertib head and neck squamous cell carcinoma sensitive detail...
Unknown unknown JPH203 + Metformin head and neck squamous cell carcinoma not applicable detail...
Unknown unknown GSK1059615 head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Prexasertib head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + Prexasertib head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + Prexasertib + Radiotherapy head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + Motolimod head and neck squamous cell carcinoma not applicable detail...
PIK3CA amp AZD8055 head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA amp Dactolisib head and neck squamous cell carcinoma sensitive detail...
PIK3CA act mut AZD8055 + Cetuximab head and neck squamous cell carcinoma predicted - sensitive detail...
Unknown unknown Cetuximab + Dasatinib head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + Cisplatin + Docetaxel + Fluorouracil head and neck squamous cell carcinoma no benefit detail...
FGFR3 positive Rogaratinib head and neck squamous cell carcinoma predicted - sensitive detail...
Unknown unknown Carboplatin + Paclitaxel + Temsirolimus head and neck squamous cell carcinoma not applicable detail...
PIK3CA E545K Carboplatin + Paclitaxel + Temsirolimus head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA mutant Carboplatin + Paclitaxel + Temsirolimus head and neck squamous cell carcinoma predicted - sensitive detail...
SMAD4 dec exp Cetuximab head and neck squamous cell carcinoma resistant detail...
SMAD4 dec exp SP600125 head and neck squamous cell carcinoma decreased response detail...
SMAD4 dec exp U0126 head and neck squamous cell carcinoma decreased response detail...
SMAD4 dec exp Cetuximab + U0126 head and neck squamous cell carcinoma sensitive detail...
SMAD4 dec exp Cetuximab + SP600125 head and neck squamous cell carcinoma sensitive detail...
DDR2 over exp Dasatinib head and neck squamous cell carcinoma sensitive detail...
FGFR2 P253R Pazopanib head and neck squamous cell carcinoma predicted - sensitive detail...
ETV6 - NTRK3 Merestinib head and neck squamous cell carcinoma sensitive detail...
Unknown unknown Adavosertib + Cisplatin + Docetaxel head and neck squamous cell carcinoma not applicable detail...
FGFR3 D764H Infigratinib head and neck squamous cell carcinoma no benefit detail...
Unknown unknown Cetuximab + Pazopanib head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + Cisplatin + Patritumab head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + Monalizumab head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + EGFR Antisense DNA + Radiotherapy head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cetuximab + EGFR Antisense DNA head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Fluorouracil + Pembrolizumab head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Cisplatin + Fluorouracil + Pembrolizumab head and neck squamous cell carcinoma not applicable detail...
PIK3CA H1047R SHR-A1307 head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA H1047R Cetuximab head and neck squamous cell carcinoma resistant detail...
PIK3CA amp Rigosertib Sodium head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 C478F GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 Q1957* GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 E1679* GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 E694* GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 C344fs GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 H2018fs GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 V489fs GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 G192* GSK2126458 head and neck squamous cell carcinoma predicted - sensitive detail...
NOTCH1 C478F PQR309 head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS mutant Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
Unknown unknown Lenvatinib + Pembrolizumab head and neck squamous cell carcinoma not applicable detail...
PIK3CA M1043V Celecoxib head and neck squamous cell carcinoma sensitive detail...
Unknown unknown Alpelisib + Cetuximab + Radiotherapy head and neck squamous cell carcinoma not applicable detail...
PIK3CA E542K Alpelisib + Cetuximab + Radiotherapy head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA H1047R Sulindac head and neck squamous cell carcinoma predicted - sensitive detail...
PIK3CA M1043V Sulindac head and neck squamous cell carcinoma sensitive detail...
PIK3CA R38C Sulindac head and neck squamous cell carcinoma sensitive detail...
PIK3CA E542K PIK3CA F744L Sulindac head and neck squamous cell carcinoma sensitive detail...
Unknown unknown Cisplatin + Docetaxel + Fluorouracil + Toripalimab head and neck squamous cell carcinoma not applicable detail...
HRAS over exp Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS over exp Alpelisib + Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS over exp Tipifarnib + Uprosertib head and neck squamous cell carcinoma predicted - sensitive detail...
HRAS over exp Sapanisertib + Tipifarnib head and neck squamous cell carcinoma predicted - sensitive detail...
Unknown unknown ALX148 + Pembrolizumab head and neck squamous cell carcinoma not applicable detail...
Unknown unknown Alpelisib + Cisplatin + Radiotherapy head and neck squamous cell carcinoma not applicable detail...
PIK3CA F977Y Pictilisib head and neck squamous cell carcinoma resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00573989 Phase Ib/II Erlotinib + Pemetrexed Disodium Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer Terminated
NCT00588770 Phase III Bevacizumab Cisplatin + Docetaxel Cisplatin + Fluorouracil Carboplatin + Docetaxel Carboplatin + Fluorouracil Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting
NCT00660218 Phase Ib/II Cetuximab + Paclitaxel A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer Unknown status
NCT00904345 Phase II Cetuximab Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) Active, not recruiting
NCT00956007 Phase III Cetuximab Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting
NCT00957853 Phase II Cetuximab Cixutumumab Preoperative Treatment With Cetuximab and/or IMC-A12 Completed
NCT01064479 Phase II Erlotinib Carboplatin Docetaxel Cisplatin Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck Active, not recruiting
NCT01104922 Phase II Cetuximab Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT01111058 Phase II Everolimus Everolimus Versus Placebo in Head and Neck Cancer Terminated
NCT01116336 Phase I Erlotinib Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck Completed
NCT01133678 Phase II Cetuximab + Cisplatin + Paclitaxel Everolimus Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck Terminated
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01316757 Phase II Carboplatin + Cetuximab + Erlotinib + Paclitaxel Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed
NCT01345669 Phase III Afatinib LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy Terminated
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01412229 Phase II Carboplatin + Cetuximab + Nab-paclitaxel Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT01437449 Phase II Cetuximab + Cisplatin + Docetaxel Carboplatin Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed
NCT01467115 Phase II Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER Completed
NCT01468896 Phase Ib/II Cetuximab Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting
NCT01488318 Phase II Cetuximab + Dasatinib Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma Terminated
NCT01577173 Phase II Cetuximab Duligotuzumab A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck Completed
NCT01581970 Phase II Cetuximab + Cyclophosphamide Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer Completed
NCT01602315 Phase Ib/II Alpelisib + Cetuximab A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Terminated
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT01612351 Phase II Carboplatin + Cisplatin + Lapatinib + Paclitaxel Carboplatin + Lapatinib + Paclitaxel Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Active, not recruiting
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting
NCT01711541 Phase Ib/II Carboplatin + Etoposide + Veliparib Cisplatin + Fluorouracil + Hydroxyurea Carboplatin + Paclitaxel Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Active, not recruiting
NCT01711658 Phase II Cisplatin + Lapatinib + Radiotherapy Cisplatin + Radiotherapy TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. (TRYHARD) Active, not recruiting
NCT01716416 Phase I Cetuximab + Pazopanib Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) Completed
NCT01737008 Phase I Cisplatin Dacomitinib Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Completed
NCT01744340 Phase Ib/II Eribulin Cetuximab A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer Completed
NCT01783587 Phase I Afatinib Docetaxel Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer Active, not recruiting
NCT01794845 Phase II Cetuximab + Docetaxel Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma Terminated
NCT01810913 Phase II Docetaxel Cisplatin Cetuximab + Docetaxel Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting
NCT01816984 Phase Ib/II Cetuximab Buparlisib PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Unknown status
NCT01824823 Phase II Afatinib Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence Active, not recruiting
NCT01836029 Phase II Cisplatin Cetuximab + Fluorouracil Carboplatin Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed
NCT01852292 Phase II Buparlisib + Paclitaxel Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Terminated
NCT01871311 Phase I Cetuximab + Nilotinib A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab Terminated
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Recruiting
NCT01935921 Phase I Cetuximab + Ipilimumab Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer Active, not recruiting
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01979211 Phase II Cetuximab Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02035527 Phase Ib/II Cisplatin + Docetaxel + Sorafenib Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed
NCT02057107 Phase II Cetuximab Docetaxel Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting
NCT02083692 Phase I Metformin Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling Completed
NCT02101034 Phase Ib/II Cetuximab + Palbociclib PD 0332991 and Cetuximab in Patients With Incurable SCCHN Active, not recruiting
NCT02105636 Phase III Methotrexate Cetuximab Docetaxel Nivolumab Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Active, not recruiting
NCT02110082 Phase I Cetuximab + Urelumab Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Completed
NCT02124707 Phase II Carboplatin + Cetuximab + Paclitaxel Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN Active, not recruiting
NCT02124850 Phase I Cetuximab A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337 Terminated
NCT02128906 Phase II Cetuximab + Docetaxel Cisplatin Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC Recruiting
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed
NCT02178072 Phase II Azacitidine Window Trial 5-aza in HNSCC, T-tare Recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Active, not recruiting
NCT02196168 Phase II Adavosertib Cisplatin Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Terminated
NCT02205398 Phase Ib/II Capmatinib + Cetuximab Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Terminated
NCT02207530 Phase II Durvalumab Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN. Active, not recruiting
NCT02241369 Phase I INO-3106 + INO-9012 Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies Completed
NCT02252042 Phase III Pembrolizumab Methotrexate Cetuximab Docetaxel Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Active, not recruiting
NCT02255097 Phase II Pembrolizumab Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) Active, not recruiting
NCT02262741 Phase I Tremelimumab Durvalumab A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer Completed
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting
NCT02270814 Phase II Carboplatin + Cetuximab + Nab-paclitaxel Cetuximab + Cisplatin + Nab-paclitaxel Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma Active, not recruiting
NCT02277184 Phase I Cisplatin + Ficlatuzumab Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Terminated
NCT02277197 Phase I Cetuximab + Ficlatuzumab Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed
NCT02282371 Phase I Alpelisib + Cetuximab Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) Active, not recruiting
NCT02289209 Phase II Pembrolizumab Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Recruiting
NCT02291055 Phase Ib/II Durvalumab ADXS11-001 Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer Active, not recruiting
NCT02296684 Phase II Pembrolizumab Cisplatin Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Recruiting
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated
NCT02319044 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02325401 Phase I Cisplatin + Metformin Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma Completed
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02334319 Phase I Ganetespib Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed
NCT02358031 Phase III Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Active, not recruiting
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated
NCT02369874 Phase III Durvalumab + Tremelimumab Durvalumab Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Active, not recruiting
NCT02375958 Phase I PCA062 PCA062 in pCAD-positive Tumors. Completed
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Completed
NCT02381535 Phase I Cisplatin Onalespib Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin Active, not recruiting
NCT02383927 Phase II Tipifarnib Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Active, not recruiting
NCT02402348 Phase I Metformin Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis Terminated
NCT02415881 Phase I Panitumumab Phase I Panitumumab IRDye800 Optical Imaging Study Recruiting
NCT02422979 Phase I ASP-1929 Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer Completed
NCT02423863 Phase II Poly ICLC In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol Recruiting
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Recruiting
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated
NCT02449681 Phase II TH-4000 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Terminated
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated
NCT02454179 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma Completed
NCT02473731 Phase I CDX-3379 A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Completed
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Active, not recruiting
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated
NCT02499120 Phase II Palbociclib Cetuximab Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer Active, not recruiting
NCT02499328 Phase Ib/II AZD9150 + Durvalumab AZD5069 + Durvalumab Durvalumab AZD9150 Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck Active, not recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Active, not recruiting
NCT02508246 Phase I Adavosertib Docetaxel Cisplatin AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck Completed
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed
NCT02537223 Phase I Alpelisib Cisplatin Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer Active, not recruiting
NCT02538510 Phase Ib/II Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Active, not recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02551159 Phase III Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Active, not recruiting
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting
NCT02555644 Phase I Prexasertib Cisplatin Cetuximab A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer Completed
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated
NCT02567422 Phase I Berzosertib + Cisplatin VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma Recruiting
NCT02573493 Phase II Cisplatin + Nab-paclitaxel Cetuximab + Nab-paclitaxel Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) Active, not recruiting
NCT02585973 Phase I Adavosertib + Cisplatin Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC Active, not recruiting
NCT02586207 Phase I Cisplatin + Pembrolizumab Pembrolizumab in Combination With CRT for LA-SCCHN Active, not recruiting
NCT02609503 Phase II Pembrolizumab Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin Active, not recruiting
NCT02626000 Phase Ib/II Pembrolizumab + Talimogene laherparepvec Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated
NCT02630420 Phase I Cetuximab + Savolitinib Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Withdrawn
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Recruiting
NCT02641093 Phase II Cisplatin Pembrolizumab Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma Recruiting
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02643550 Phase Ib/II Cetuximab + Monalizumab Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT02644122 Phase II SF1126 SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes Terminated
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02649530 Phase II LGK974 An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma Withdrawn
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Completed
NCT02665416 Phase I RO5520985 + Selicrelumab Bevacizumab + Selicrelumab Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Completed
NCT02684253 Phase II Nivolumab Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Active, not recruiting
NCT02706691 Phase II Infigratinib Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer Terminated
NCT02734537 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting
NCT02741570 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02762513 Phase II Axitinib Expansion Trial for Axitinib In Head And Neck Cancer Active, not recruiting
NCT02764593 Phase I Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma Active, not recruiting
NCT02769520 Phase II Pembrolizumab Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Recruiting
NCT02775812 Phase I Cisplatin + Pembrolizumab Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting
NCT02777385 Phase II Cisplatin + Pembrolizumab Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Recruiting
NCT02812524 Phase I Ipilimumab Ipilimumab for Head and Neck Cancer Patients Recruiting
NCT02823574 Phase II Nivolumab Ipilimumab + Nivolumab Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02827838 Phase I Durvalumab Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Recruiting
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Completed
NCT02892201 Phase II Pembrolizumab Pembrolizumab in HNSCC With Residual Disease After Radiation Active, not recruiting
NCT02949700 Phase Ib/II Cisplatin + Metformin Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma Recruiting
NCT02952586 Phase III Cisplatin Avelumab + Cisplatin Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Terminated
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT02979977 Phase II Afatinib + Cetuximab Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck Recruiting
NCT02989064 Phase I MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers Active, not recruiting
NCT02990468 Phase I BMX-001 + Cisplatin A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN) Active, not recruiting
NCT02994069 Phase II Cisplatin Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers Recruiting
NCT03019003 Phase Ib/II Azacitidine + Durvalumab + Tremelimumab A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients Recruiting
NCT03022409 Phase I Olaparib AZD6738 A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Active, not recruiting
NCT03049618 Phase II Pembrolizumab + sEphB4-HSA Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Recruiting
NCT03057613 Phase II Pembrolizumab A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck Recruiting
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting
NCT03071757 Phase I ABBV-368 ABBV-368 + Nivolumab A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03076281 Phase II Doxycycline Doxycycline + Metformin Metformin Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Active, not recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status
NCT03082534 Phase II Cetuximab + Pembrolizumab Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting
NCT03083873 Phase II LN-145 Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck Recruiting
NCT03085719 Phase II Pembrolizumab Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN Recruiting
NCT03098160 Phase I Evofosfamide + Ipilimumab Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Unknown status
NCT03109158 Phase Ib/II Cetuximab + Fluorouracil + NC-6004 NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Active, not recruiting
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03138070 Phase I Alpelisib A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 Recruiting
NCT03138889 Phase I NKTR-214 + Pembrolizumab A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL) Recruiting
NCT03153982 Phase II Ruxolitinib Ruxolitinib in Operable Head and Neck Cancer Recruiting
NCT03162224 Phase Ib/II Durvalumab + MEDI0457 Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer Active, not recruiting
NCT03162731 Phase I Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer Active, not recruiting
NCT03174275 Phase II Carboplatin + Cisplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Paclitaxel Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma Recruiting
NCT03194373 Phase II Carboplatin + Palbociclib Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Recruiting
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Recruiting
NCT03238638 Phase II Epacadostat + Pembrolizumab A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Withdrawn
NCT03245489 Phase I Pembrolizumab Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT03246685 Phase II Pembrolizumab + PGG beta-glucan Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD Terminated
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Recruiting
NCT03247712 Phase Ib/II Nivolumab Neoadjuvant Immunoradiotherapy in Head & Neck Cancer Recruiting
NCT03254927 Phase II CDX-3379 + Cetuximab A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma Recruiting
NCT03258554 Phase II Cetuximab Durvalumab Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin Recruiting
NCT03264066 Phase II Atezolizumab + Cabozantinib A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors Completed
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Active, not recruiting
NCT03283605 Phase Ib/II Durvalumab + Tremelimumab Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03301896 Phase I LHC165 + Spartalizumab LHC165 Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Recruiting
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Recruiting
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Active, not recruiting
NCT03325465 Phase II Epacadostat + Pembrolizumab Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck Withdrawn
NCT03336606 Phase I Tavolimab Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma Recruiting
NCT03341936 Phase II Lirilumab + Nivolumab Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT03342352 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab Carboplatin + Cisplatin + Fluorouracil + Nivolumab Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) Withdrawn
NCT03342911 Phase II Carboplatin + Nivolumab + Paclitaxel Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Suspended
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated
NCT03349710 Phase III Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting
NCT03358472 Phase III Pembrolizumab Carboplatin + Fluorouracil Epacadostat + Pembrolizumab Cetuximab + Cisplatin Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated
NCT03370276 Phase Ib/II Cetuximab + Nivolumab Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting
NCT03381183 Phase Ib/II Cyclophosphamide + Durvalumab + Tremelimumab IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma Recruiting
NCT03386838 Phase III BMS-986205 + Nivolumab Carboplatin + Cetuximab + Cisplatin + Fluorouracil An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck Withdrawn
NCT03387111 Phase Ib/II Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Active, not recruiting
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Recruiting
NCT03422536 Phase II Ficlatuzumab Cetuximab + Ficlatuzumab Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT03447314 Phase I GSK1795091 + GSK3174998 GSK3174998 Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors Active, not recruiting
NCT03452137 Phase III Atezolizumab A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT03463161 Phase II Epacadostat + Pembrolizumab Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy (ORKA) Terminated
NCT03468218 Phase II Cabozantinib + Pembrolizumab Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy Recruiting
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting
NCT03485209 Phase II Tisotumab Vedotin Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting
NCT03498378 Phase I Avelumab + Cetuximab + Palbociclib Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT03509012 Phase I Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Active, not recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03521570 Phase II Nivolumab Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Recruiting
NCT03522584 Phase Ib/II Durvalumab + Tremelimumab Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT03524326 Phase I Cetuximab + Lenvatinib Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Recruiting
NCT03529422 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Recruiting
NCT03544723 Phase II Nivolumab Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Ad-p53 in Head and Neck Cancer Recruiting
NCT03546582 Phase II Pembrolizumab SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE) Recruiting
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting
NCT03565783 Phase II Cemiplimab Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT03589339 Phase I NBTXR3 NBTXR3 + unspecified PD-1 antibody NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Recruiting
NCT03590054 Phase I Abexinostat + Pembrolizumab A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Active, not recruiting
NCT03618654 Phase I Durvalumab + Metformin Durvalumab Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Recruiting
NCT03625323 Phase II Eftilagimod alpha + Pembrolizumab Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Active, not recruiting
NCT03635164 Phase I Durvalumab Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma Recruiting
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Recruiting
NCT03645928 Phase II LN-144 + Pembrolizumab LN-145 LN-145 + Pembrolizumab Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Recruiting
NCT03646461 Phase II Ibrutinib + Nivolumab Cetuximab + Ibrutinib Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC Recruiting
NCT03650764 Phase Ib/II Pembrolizumab + Ramucirumab Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT03652233 Phase I Afatinib + Nivolumab Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Withdrawn
NCT03655444 Phase Ib/II Abemaciclib + Nivolumab Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy Recruiting
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Recruiting
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Recruiting
NCT03667482 Phase I Cabozantinib + Cetuximab Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03690986 Phase I Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer Recruiting
NCT03691714 Phase II Cetuximab + Durvalumab Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated
NCT03708224 Phase II Atezolizumab + Emactuzumab Atezolizumab Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma Recruiting
NCT03719690 Phase II Tipifarnib Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) Recruiting
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Recruiting
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03740100 Phase II PQR309 Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC) Recruiting
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Recruiting
NCT03769311 Phase II Cetuximab Cetuximab in Head and Neck Cancer Patients Suspended
NCT03771820 Phase II Pembrolizumab NC-6004 + Pembrolizumab Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen Recruiting
NCT03789097 Phase Ib/II CDX-301 + Pembrolizumab + Poly ICLC Vaccination With Flt3L, Radiation, and Poly-ICLC Recruiting
NCT03795610 Phase II IPI-549 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Recruiting
NCT03803774 Phase I Birinapant Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma Recruiting
NCT03809624 Phase I INBRX-105 Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (PDL1x41BB) Recruiting
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed
NCT03823131 Phase II Epacadostat + Pembrolizumab + Tavokinogene telseplasmid Tavokinogene Telseplasmid With Electroporation, Pembrolizumab, and Epacadostat in Treating Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03854032 Phase II Nivolumab BMS-986205 + Nivolumab Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck Recruiting
NCT03871348 Phase I SAR441000 Cemiplimab + SAR441000 A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Recruiting
NCT03878979 Phase II Nivolumab Preoperative Immune Checkpoint Inhibitor for Patients With Recurrent or Metastatic SCCHN Undergoing Surgical Salvage Recruiting
NCT03893955 Phase I ABBV-368 + ABBV-927 ABBV-181 + ABBV-368 + ABBV-927 Docetaxel A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting
NCT03916627 Phase II Cemiplimab Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC Recruiting
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Recruiting
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting
NCT03937141 Phase II MIW815 Efficacy and Safety Trial of ADU-S100 and Anti-PD1 in Head and Neck Cancer Recruiting
NCT03938337 Phase II Abemaciclib + Pembrolizumab Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer Active, not recruiting
NCT03944915 Phase II Carboplatin + Nivolumab + Paclitaxel Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND) Recruiting
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Recruiting
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Suspended
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Recruiting
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Recruiting
NCT03978689 Phase I CUE-101 A Phase 1 Study in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Not yet recruiting
NCT03993353 Phase II Pembrolizumab + Tadalafil Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Recruiting
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Recruiting
NCT04000529 Phase I Spartalizumab + TNO155 Ribociclib + TNO155 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Recruiting
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Recruiting
NCT04034225 Phase Ib/II PAN-301-1 + Pembrolizumab Addition of SNS-301 to Ongoing Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN Recruiting
NCT04052204 Phase II Avelumab + NKTR-214 Avelumab + NKTR-214 + Talazoparib Avelumab + Enzalutamide + NKTR-214 Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Active, not recruiting
NCT04058145 Phase II Pembrolizumab + Plerixafor AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Not yet recruiting
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting
NCT04069026 Phase I BAY2416964 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer Recruiting
NCT04080804 Phase II Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer Recruiting
NCT04091867 Phase I Cetuximab + sEphB4-HSA sEphB4-HSA With Cetuximab and RT in Patients With High Risk, LAHNSCC and Heavy Smoking Histories Recruiting
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT04107103 Phase II Nivolumab + Pemetrexed Disodium Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus) Recruiting
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Not yet recruiting
NCT04122625 Phase Ib/II Debio 1143 + Nivolumab Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Recruiting
NCT04128696 Phase III Pembrolizumab GSK3359609 + Pembrolizumab Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) Recruiting
NCT04135352 Phase I Pembrolizumab + V938 A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) Recruiting
NCT04144517 Phase II ALKS 4230 + Pembrolizumab A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer Recruiting
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting
NCT04150900 Phase II Bavituximab + Pembrolizumab 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck Recruiting
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting
NCT04180215 Phase Ib/II HB-201 + HB-202 HB-201 + Nivolumab HB-201 HB-201 + HB-202 + Nivolumab A Study of TheraT Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers Recruiting
NCT04188951 Phase I Pembrolizumab HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer Recruiting
NCT04193293 Phase Ib/II Duvelisib + Pembrolizumab A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer Recruiting
NCT04196283 Phase I ABBV-368 + IMO-2125 ABBV-368 + IMO-2125 + Nab-paclitaxel ABBV-181 + ABBV-368 + IMO-2125 + Nab-paclitaxel A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting
NCT04220775 Phase Ib/II M7824 M7824 Plus Re-irradiation With Stereotactic Body Radiation Therapy for the Curative Intent Treatment of Recurrent Head and Neck Cancer Recruiting
NCT04220866 Phase II MK-1454 + Pembrolizumab Pembrolizumab Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) Recruiting
NCT04247282 Phase Ib/II M7824 ETBX-011 + ETBX-051 + ETBX-061 + M7824 ALT-803 + ETBX-011 + ETBX-051 + ETBX-061 + M7824 Anti-PD-L1/TGF- <= Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for p16-Negative Resectable Head and Neck Squamous Cell Carcinoma Recruiting
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Not yet recruiting
NCT04262388 Phase II Durvalumab + Oleclumab A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Not yet recruiting
NCT04266730 Phase I PANDA-VAC + Pembrolizumab + Poly ICLC Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) Not yet recruiting
NCT04290546 Phase I ALT-803 + CIML-NK cells + Ipilimumab ALT-803 + CIML-NK cells CIML NK Cell in Head & Neck Cancer Recruiting
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting
NCT04313504 Phase II Dostarlimab + Niraparib Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC Not yet recruiting
NCT04326257 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy Recruiting
NCT04340258 Phase Ib/II Pembrolizumab Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC Not yet recruiting
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Recruiting
NCT04349267 Phase Ib/II BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors Recruiting
NCT04369937 Phase II Cisplatin + ISA101b + Pembrolizumab HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma Recruiting
NCT04375384 Phase II Cetuximab Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy Recruiting
NCT04389632 Phase I A Study of SGN-B6A in Advanced Solid Tumors Recruiting
NCT04414540 Phase II Metformin + Pembrolizumab Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients Not yet recruiting
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting
NCT04428151 Phase II Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) Recruiting
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting
NCT04452214 Phase I Nidanilimab + Pembrolizumab A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors Not yet recruiting
NCT04454489 Phase II Pembrolizumab Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Not yet recruiting
NCT04470024 Phase I DPV-001 + INCAGN01876 + Retifanlimab DPV-001 + Retifanlimab Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC Not yet recruiting
NCT04471415 Phase Ib/II DRP-104 Atezolizumab + DRP-104 First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. Not yet recruiting
NCT04477759 Phase I Atezolizumab Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) Not yet recruiting